Gubra A/S engages in providing research and development services to pharmaceutical and biotechnology companies on a contract basis. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The firm's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
Gubra A/S hisse başına yıllık % {var1} temettüye sahiptir ve % {var2} oranında bir getiri sunmaktadır. Temettü diğer/bilinmiyor ödenmektedir ve son temettü hariç tarihi Jun 30, 2025 tarihindedir.
Dividend Yield
Yıllık Dividende
Özsermaye Tarihi
0.00%
$0.00
Jun 30, 2025
Ödeme Sıklığı
Ödeme Oranı
Diğer/Bilinmiyor
0.00%
Dividend History
Özsermaye Tarihi
Nakit Tutarı
Kayıt Tarihi
Ödeme Tarihi
Jun 30, 2025
$61.20
Jul 1, 2025
Jul 2, 2025
Dividend Grafikleri
GUBRF Kâr Payları
GUBRF Dividend Growth (Yıllık Üstünlük)
Follow-Up Questions
Gubra A/S'in şu anki temettü ödemesi ve yıllık temettüsü nedir?